# IDEXX Laboratories, Inc. (IDXX) — Narrative, Q3 2026

## Business

*Source: Form 10-K for the fiscal year ended December 31, 2025 (accession 0000874716-26-000038), Items 1 and 7.*

IDEXX sells diagnostic instruments, consumables, laboratory testing and practice software to veterinarians, overwhelmingly for dogs and cats, with smaller businesses in water-quality testing and livestock, poultry and dairy diagnostics. In 2025 the company reported revenue of $4.30 billion, of which the Companion Animal Group (CAG) contributed $3.95 billion. The economic engine is recurring: IDEXX places analyzers in veterinary clinics, often free or discounted under multi-year purchase commitments, and then earns most of its revenue and margin from the consumables, rapid tests and reference-lab work those customers buy every day. Recurring diagnostic revenue was about 79% of consolidated revenue in 2025, and the company describes the multi-year consumable stream as "significantly more valuable than the placement of the instrument." About 36% of 2025 revenue came from customers outside the U.S.

IDEXX reports three segments plus an Other category:

- **Companion Animal Group (CAG)** — 2025 revenue $3,953.3 million. CAG Diagnostics recurring revenue ($3,407.2 million) comprises:
  - IDEXX VetLab consumables ($1,496.8 million), used in the in-clinic analyzer suite: Catalyst One/Catalyst Dx chemistry, ProCyte One/ProCyte Dx hematology, SediVue Dx urinalysis, and the IDEXX inVue Dx cellular analyzer launched in late 2024, which automates cytology and blood-morphology testing with AI-driven optics.
  - Reference laboratory diagnostic and consulting services ($1,424.1 million) from a network of approximately 80 laboratories serving the U.S., Europe, Canada, Australia, Japan, New Zealand, South Africa and South Korea, mostly with same-day or next-day results.
  - SNAP rapid assay test kits ($349.0 million), such as SNAP 4Dx Plus for canine vector-borne disease and heartworm. Sales are seasonal and run heavier in the first half of the year.
  - Diagnostic services and accessories ($137.4 million).

  CAG also includes instrument sales ($200.2 million) and veterinary software, services and diagnostic imaging ($345.9 million). The software business covers the cloud practice-management systems ezyVet, Animana and IDEXX Neo, on-premises Cornerstone, Web PACS imaging software and the ImageVue DR50/DR30 digital radiography systems; the DR50 Plus launched in North America in January 2026. VetConnect PLUS ties the results from every modality into a single cloud-based patient record.
- **Water** — 2025 revenue $201.1 million. Tests such as Colilert, Colilert-18 and Colisure detect coliforms and *E. coli* in drinking water. They sell to utilities, government laboratories and certified private laboratories, and demand is largely driven by regulation; several products carry EPA approval.
- **Livestock, Poultry and Dairy (LPD)** — 2025 revenue $131.8 million. Diagnostic tests for diseases such as BVDV, PRRS and TSE, cattle pregnancy tests, and SNAP tests that detect antibiotic residue in milk. About 81% of LPD revenue is earned outside the U.S.
- **Other** — 2025 revenue $17.5 million: human point-of-care electrolyte and blood-gas analyzers, plus an out-licensing arrangement.

The installed base of premium instruments at December 31, 2025 was about 78,000 Catalyst, 56,000 premium hematology, 24,000 SediVue Dx and 6,000 inVue Dx units. In the U.S., IDEXX sells companion-animal products directly to veterinarians; internationally it uses its own sales force and, in certain countries, distributors. Main competitors include Mars, Incorporated (Antech Diagnostics, Heska, VCA), Zoetis (including Abaxis), Fujifilm and Mindray in diagnostics, and Covetrus in practice-management software. Many Catalyst chemistry slides are sole-sourced from Ortho-Clinical Diagnostics under supply agreements that run to December 2044. IDEXX had about 11,000 employees at the end of 2025.

## Risk factors

*Source: Form 10-K for fiscal 2025 (accession 0000874716-26-000038), Item 1A. The Form 10-Q for the quarter ended September 30, 2026 (accession 0000874716-26-000135) reports no material changes to these risk factors.*

The risks most specific to IDEXX's model are these:

- **Competition and pricing power.** IDEXX expects competition to intensify, from existing rivals and new entrants drawn by the sector's growth and returns. Its strategy depends on keeping premium pricing and pushing through price increases while competitors sell "lesser offerings at lower prices." Rivals that move faster on new technology, including AI, could make some products obsolete.
- **Customer consolidation and vertical integration.** A growing share of U.S. veterinary hospitals is corporately owned, by groups such as Mars (Banfield, BluePearl, VCA) and National Veterinary Associates. Many independent practices also buy through consortiums. These buyers use scale to win lower prices. Some corporate owners run their own reference labs and sell point-of-care instruments, so clinics they acquire may move testing away from IDEXX.
- **Supplier concentration.** Many products, components and materials come from sole or single sources, including Ortho for Catalyst slides. Some are proprietary and hard to replace. A supply disruption could cost IDEXX customers and recurring revenue, and some contracts carry minimum purchase obligations.
- **Biologic manufacturing.** Rapid assay, livestock, water and dairy products contain antibodies, cells and sera. These products are hard to make consistently, and product failures can lead to recalls.
- **Testing patterns and clinic traffic.** Demand depends on how many pets visit clinics and how intensively they are tested. New vaccines or preventatives, changes in medical protocols, disease eradication, or a smaller pet population could all reduce testing. Pet owners pay out of pocket, so economic weakness can lead them to postpone visits or decline tests. LPD demand moves with disease outbreaks such as African swine fever and with government funding.
- **Innovation and AI.** Growth depends on continued product launches and on building AI into products and operations. The AI risks named include flawed models, uncertain IP rights, new cybersecurity exposure and evolving regulation, including the EU AI Act, which becomes fully effective in August 2026.
- **Regulation.** Many products need USDA, FDA or EPA approval, and foreign registrations are required as well. Government shutdowns can delay those reviews. Chemical rules on PFAS, REACH and RoHS could force products to be redesigned.
- **Operational concentration.** Many major products are made in Southern Maine, with other manufacturing in Roswell, Georgia; Bern, Switzerland; and Montpellier, France. A disruption at any key plant, distribution center or laboratory could hurt results.
- **Currency.** About 23% of 2025 revenue came from products made or sourced in U.S. dollars and sold abroad in local currencies, so a stronger dollar reduces both revenue and profit. IDEXX aims to hedge 75–85% of its intercompany product exposure in five major currencies, using contracts that generally run less than 24 months, so hedging delays the effect of a stronger dollar rather than removing it.
- **Leadership transition, cybersecurity and privacy.** The CEO changed on May 12, 2026, when Mike Erickson succeeded Jay Mazelsky, who became Executive Chair. The cloud software and connected analyzers create cyber exposure, and IDEXX notes it has experienced attacks before, though none with a material impact. The business is also subject to GDPR and U.S. state privacy laws.
- **Debt, taxes and stock volatility.** Credit Facility borrowings carry variable rates, and the senior notes carry prepayment penalties. Tax law changes, such as those affecting FDII and share-based compensation benefits, can move the effective rate. The stock traded between $361.04 and $766.68 in 2025.

## Management's discussion — fiscal 2025

*Source: Form 10-K for fiscal 2025 (accession 0000874716-26-000038), Item 7 and the Consolidated Statements of Income.*

In 2025 revenue grew 10.4% to $4,303.7 million, or 9.6% on an organic basis; currency added 0.8 points. Most of the growth came from CAG Diagnostics recurring revenue (+8.9% reported, +8.1% organic), through higher volumes and higher realized prices:

- VetLab consumables rose 14.8%, helped by 12% growth in the premium-instrument installed base and an expanded test menu.
- Reference-lab revenue rose 6.6% on volume growth in North America, Europe and Asia Pacific and on pricing.
- Rapid assay revenue fell 3.0% as customers moved pancreatic-lipase testing onto the Catalyst platform and as macroeconomic and sector headwinds weighed on testing.
- Instrument revenue jumped 51.8% to $200.2 million on placements of the new inVue Dx.
- Software and imaging grew 10.6%.
- Water grew 8.7% and LPD 8.0%.

This growth came in a weak traffic environment. U.S. same-store clinical visits fell about 2% in 2025, held back by capacity constraints in veterinary practices and by macroeconomic headwinds. Even so, average diagnostics revenue per U.S. practice grew about 6% on a same-store basis, against roughly 2% growth in overall practice revenue. Management's initial 2026 outlook assumed a similar decline in U.S. same-store clinical visits.

Margins widened sharply. Gross margin rose 80 basis points to 61.8% on consumable and reference-lab volume, productivity and pricing, partly offset by the lower-margin mix from higher instrument sales. Operating income rose 20.5% to $1,360.0 million, and the operating margin reached 31.6%, up from 29.0%. Part of the margin gain came from a favorable comparison: general and administrative expense fell 8.5% because 2024 included a $61.5 million litigation charge and 2025 included a reversal of about $9 million of the related accrual. That royalty dispute ended with a payment of about $80 million in April 2025.

Net income was $1,059.5 million, or $13.08 per diluted share, compared with $887.9 million and $10.67 in 2024. The effective tax rate was 20.0% in both years. Interest expense rose to $38.9 million on higher debt and rates, and interest income fell to $3.0 million.

Operating cash flow was about $1.2 billion, up $252.8 million. Financing activities used about $1.2 billion. Share repurchases took $379.9 million more cash than in 2024 (about 2.4 million shares were bought), and the company repaid $103.4 million of euro-denominated Series C notes and $75.0 million of Series B notes at maturity; these outflows were partly offset by $148.0 million of Credit Facility borrowings. Year-end cash was $180.1 million, with $398.0 million drawn on the $1.25 billion Credit Facility, which includes a $250.0 million term loan swapped to a fixed rate of about 3.4% plus spread through November 2028. IDEXX pays no dividend and returns capital through buybacks.

## Current quarter — three and nine months ended September 30, 2026

*Source: Form 10-Q for the quarter ended September 30, 2026 (accession 0000874716-26-000135), Item 1 (statements and Notes 4, 11, 12, 18) and Item 2; earnings release furnished as Exhibit 99.1 to Form 8-K dated November 2, 2026 (accession 0001104659-26-120892).*

**Results.** Third-quarter revenue rose 9.9% to $1,214.2 million, or 10.0% organic; currency trimmed 0.2 points. CAG revenue grew 10.2% to $1,116.0 million (10.4% organic). CAG Diagnostics recurring revenue rose 10.8% to $967.4 million (11.0% organic), driven by volume growth from existing and new customers, an expanded test menu and higher realized prices:

- VetLab consumables grew 14.3% to $443.2 million, supported by 11% growth in the premium-instrument installed base.
- Reference-lab revenue grew 10.0% to $399.1 million.
- Rapid assay revenue was up only 0.6% to $89.1 million. Higher prices were mostly offset by lower point-of-care vector-borne disease testing volumes and the continued shift of pancreatic-lipase testing to Catalyst.
- Instrument revenue was flat at $51.5 million. More SediVue Dx and inVue Dx placements were offset by lower price realization from placement programs. The earnings release reports more than 1,900 inVue Dx placements in the quarter, bringing that installed base to nearly 11,000.
- Software, services and imaging grew 10.6% to $97.1 million.
- Water grew 8.4% to $58.8 million on pricing and Colilert demand in the Americas. LPD grew 2.6% to $34.8 million; gains in the Americas were partly offset by lower swine testing in Asia.

Gross margin expanded 110 basis points to 62.9%. Operating expenses rose 10.2%; general and administrative expense grew 16.4% on consulting fees, compensation and technology depreciation. Operating income rose 13.4% to $402.3 million, and the operating margin was 33.1%, up from 32.1%. Interest expense fell to $7.5 million from $10.7 million on lower average debt, and an equity investment produced a $3.5 million gain. Net income was $317.1 million, or $4.01 per diluted share, up from $274.6 million and $3.40. The quarterly effective tax rate was 20.6%.

For the nine months, revenue rose 11.2% to $3,571.6 million (10.0% organic, with currency adding 1.1 points). Operating income was $1,190.5 million, a 33.3% margin. Net income was $934.0 million and diluted EPS $11.75, compared with $811.3 million and $9.99. The nine-month figures include a $5 million impairment of an equity investment in the first quarter.

**CoVet acquisition.** On September 15, 2026, IDEXX acquired 100% of CoVetAI Inc. ("CoVet"), which makes AI-native ambient-listening and clinical-workflow software for veterinary practices. The price was about $250 million, which includes an estimated $20 million contingent payment and about $4 million of holdbacks. The contingent consideration could pay anywhere from zero to $47.5 million, depending on annual revenue targets for 2027 through 2029; its acquisition-date fair value was $20.2 million. The provisional purchase price allocation assigns about $230 million to goodwill, about $12 million to technology intangibles (three-year life) and about $13 million to customer relationships (nine-year life), net of about $5 million of net tangible liabilities assumed. Replacement awards for unvested CoVet equity, worth about $7 million in cash and stock, will be expensed over three years. CoVet sits in CAG, and its revenue contribution in the quarter was immaterial. The cash outflow for the acquisition, net of cash acquired, was $223.4 million.

**Cash, capital and balance sheet.** Nine-month operating cash flow rose to $1,063.1 million from $826.0 million. The prior-year period had included the roughly $80 million litigation payment and higher tax payments. Capital expenditures were $85.6 million, and the 2026 capital plan was cut to about $160 million from the $180 million projected in February. IDEXX repurchased 1.37 million shares in the open market for $804.7 million (average $588.14) over nine months, slowing to 199,000 shares ($111.8 million) in the third quarter; about 2.35 million shares remained under the authorization at September 30.

On September 4, 2026, IDEXX repaid its $75.0 million 3.72% 2026 Senior Notes at maturity. Credit Facility borrowings rose to $474.0 million, leaving $773.2 million of availability, and senior notes outstanding fell to $375.0 million. The $75.0 million 2027 Series B notes come due on February 12, 2027. The covenant leverage ratio was 0.5 to 1, against a 3.5 to 1 limit. Cash was $197.5 million, goodwill rose to $640.5 million from $414.0 million (CoVet added about $230 million), and stockholders' equity was $1,869.2 million. Under customer commitment arrangements, IDEXX expects about $5.3 billion of future revenue.

**Outlook (November 2, 2026).** IDEXX raised its 2026 guidance:

| Metric | Updated | Prior |
|---|---|---|
| Revenue | $4,741–$4,767 million | $4,700–$4,745 million |
| Reported revenue growth | 10.1%–10.8% | 9.1%–10.3% |
| Organic revenue growth | 9.3%–10.0% | 8.5%–9.7% |
| CAG Diagnostics recurring growth, reported | 11.0%–11.7% | 10.1%–11.3% |
| CAG Diagnostics recurring growth, organic | 10.3%–11.0% | 9.5%–10.7% |
| Operating margin | 32.1%–32.3% | 32.3%–32.5% |
| EPS | $14.96–$15.16 | $14.69–$14.94 |
| Effective tax rate | ~20.5% | ~21.1% |
| Capital expenditures | ~$160 million | ~$180 million |

The revenue midpoint rose $32 million, of which about $5 million comes from CoVet. Operating-margin guidance was lowered to reflect acquisition-related impacts, but it still implies 50–70 basis points of full-year expansion. Currency is expected to add about $0.25 to 2026 EPS. IDEXX also announced an investor session for January 18, 2027 to present its next point-of-care analyzer, IDEXX MultiCue Dx.

## Subsequent events

*Source: Form 10-Q for the quarter ended September 30, 2026 (accession 0000874716-26-000135); Form 10-K for fiscal 2025 (accession 0000874716-26-000038).*

The quarterly report, filed November 2, 2026, has no subsequent-events note. It discloses no acquisition, divestiture, financing or litigation outcome after September 30, 2026. The CoVet acquisition (September 15, 2026) and the repayment of the 2026 Senior Notes (September 4, 2026) both happened within the quarter and are described above. The 10-Q cover reports 78,786,265 common shares outstanding on October 28, 2026. The fiscal 2025 annual report also has no subsequent-events note.